🤖 Search 5,000+ AI tools Ask our bot for help →

Discover the latest tools and trends in AI 🔮

Join 60,000+ subscribers including Amazon, Apple, Google, and Microsoft employees reading our free newsletter.

[email protected] Subscribe

Valar Labs nets $22M in Series A round

Valar Labs nets $22M in Series A round
Valar Labs nets $22M in Series A round

Valar Labs, based in Palo Alto, CA, raises $22M in Series A funding to advance AI cancer therapy tests.

The round was led by DCVC and Andreessen Horowitz Bio + Health, with Pear VC participating. Joining the board are Vineeta Agarwala, MD, PhD from a16z Bio + Health, and James Hardiman from DCVC.

Funds will be used to expand operations and R&D efforts. Valar Labs specializes in computational histology AI tests, such as their bladder cancer test, Vesta, which predicts patient outcomes for BCG therapy.

Valar Labs operates a CLIA-certified lab in Houston, Texas, enhancing patient and physician treatment decisions based on tumor biology.

Comments